Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03329287
Other study ID # 15411950201
Secondary ID
Status Recruiting
Phase N/A
First received October 26, 2017
Last updated October 29, 2017
Start date July 1, 2017
Est. completion date June 30, 2018

Study information

Verified date July 2017
Source Shanghai Mental Health Center
Contact Chunbo Li, PHD
Phone 86-21-34773243
Email chunbo_li@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial attempts to evaluate the treatment efficacy of Simplified Cognitive Behavioral Therapy (SCBT) and its safety among schizophrenia patients. Half of participants will be randomized to accept SCBT.


Description:

The investigators have developed a simplified but standardized set of cognitive behavioral treatment (including the therapist's manual and patient self-help manual) for the patients of generalized anxiety disorder and depression, known as Simplified Cognitive Behavioral Therapy (SCBT). SCBT is the main psychological intervention of this study. The aim of this study is to verify its efficacy and applicability using a multi-center, randomized, placebo controlled and single-blind design, and to optimize the treatment program. The investigators hypothesize that SCBT is effective in patients with depression or anxiety, and the manual is easily-operated for the therapists.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date June 30, 2018
Est. primary completion date March 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- 1. Adults aged 18-60 years old, male and female; 2. With primary school or above education levels; 3. Without vision, hearing or communication difficulties; 4. DSM-V diagnosis of generalized anxiety disorder and/or major depressive disorder; 5. HAMA-14 score greater than or equal to 14 points, less than 29 pionts; HAMD-17 score greater than or equal to 7 points, less than 24 points; 6. GAD-7 score greater than or equal to 5 points; PHQ-9 score greater than or equal to 5 points; 7. In the last 2 months, did not accept other forms of psychological treatment, or treatment is ineffective; 8. Voluntarily participate in and sign informed consent.

Exclusion Criteria:

1. Suffering from serious physical illness;

2. Having self-injurious behavior, suicidal tendencies;

3. Having bipolar disorder;

4. Having psychotic symptoms;

5. Having obsessive-compulsive disorder, post-traumatic stress disorder;

6. Pregnant women or lactating women.

Study Design


Intervention

Behavioral:
SCBT
SCBT, one hour per session.
Drug:
SSRIs and/or SNRIs
SSRIs and/or SNRIs at a recommended dosage.
Behavioral:
Psychological Placebo
Supportive and relaxation therapy, one our per session.

Locations

Country Name City State
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (6)

Lead Sponsor Collaborator
Shanghai Mental Health Center Changhai Hospital, Fudan University, Second Hospital of Shanxi Medical University, Shanghai 10th People's Hospital, Tongji Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary changes of The Hamilton Depression Scale (HAMD-17) Scale total range is 52. Lower score represents a better outcome. At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
Primary changes of The Hamilton Anxiety Scale (HAMA-14) Scale total range is 56. Lower score represents a better outcome. At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
Secondary changes of The Patient Health Questionnaire (PHQ-9) Scale total range is 27. Lower score represents a better outcome. At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
Secondary changes of The GAD-7 Scale total range is 21. Lower score represents a better outcome. At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
Secondary changes of The Mos 36-item Short Form Health Survey (SF-36) It has nine dimensions, each dimension has an independent fractional formula. At baseline, 4-week, 8-week, 12-week, 20-week, 32-week and 56-week.
Secondary changes of Treatment Emergent Symptom Scale (TESS) Evaluation of side effects caused by various psychotropic drugs. At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
Secondary changes of Clinical Global Impression (CGI) Evaluation of clinical efficacy. Lower score represents a better outcome. At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A